{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/sickle-cell-disease/how-this-topic-was-developed/stakeholder-engagement/","result":{"pageContext":{"chapter":{"id":"acc3b704-7f3d-51ed-869e-38e0309c53e5","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement","depth":2,"htmlHeader":"<!-- begin field fe63e9c7-fb7e-4b25-bad0-a7f201750b43 --><h2>Stakeholder engagement</h2><!-- end field fe63e9c7-fb7e-4b25-bad0-a7f201750b43 -->","summary":null,"htmlStringContent":"<!-- begin item fb586e9f-4f35-47f6-a604-a7f20174d91e --><!-- begin field ae45ac5f-f82c-48e5-8ce5-a7f201750b43 --><h2>Our policy</h2><!-- end field ae45ac5f-f82c-48e5-8ce5-a7f201750b43 --><!-- begin field ccceac8d-c351-496f-91ff-a7f201750b43 --><p>The external review process is an essential part of CKS topic development. Consultation with a wide range of stakeholders provides quality assurance of the topic in terms of:</p><ul><li>Clinical accuracy.</li><li>Consistency with other providers of clinical knowledge for primary care.</li><li>Accuracy of implementation of national guidance (in particular NICE guidelines).</li><li>Usability.</li></ul><!-- end field ccceac8d-c351-496f-91ff-a7f201750b43 --><!-- begin field 8883c4f9-6c60-42e8-a09d-a7f201750b43 --><h2>Principles of the consultation process</h2><!-- end field 8883c4f9-6c60-42e8-a09d-a7f201750b43 --><!-- begin field 19e16560-3747-40e8-9663-a7f201750b43 --><ul><li>The process is inclusive and any individual may participate.</li><li>To participate, an individual must declare whether they have any competing interests or not. If they do not declare whether or not they have competing interests, their comments will not be considered.</li><li>Comments received after the deadline will be considered, but they may not be acted upon before the clinical topic is issued onto the website.</li><li>Comments are accepted in any format that is convenient to the reviewer, although an electronic format is encouraged.</li><li>External reviewers are not paid for commenting on the draft topics.</li><li>Discussion with an individual or an organization about the CKS response to their comments is only undertaken in exceptional circumstances (at the discretion of the Clinical Editor or Editorial Steering Group).</li><li>All reviewers are thanked and offered a letter acknowledging their contribution for the purposes of appraisal/revalidation.</li><li>All reviewers are invited to be acknowledged on the website. All reviewers are given the opportunity to feedback about the external review process, enabling improvements to be made where appropriate.</li></ul><!-- end field 19e16560-3747-40e8-9663-a7f201750b43 --><!-- begin field 9481e6b6-97f5-43b0-b1ad-a7f201750b43 --><h2>Stakeholders</h2><!-- end field 9481e6b6-97f5-43b0-b1ad-a7f201750b43 --><!-- begin field c4fb8b6a-1691-4abc-9e9c-a7f201750b43 --><ul><li>Key stakeholders identified by the CKS team are invited to comment on draft CKS topics. Individuals and organizations can also register an interest to feedback on a specific topic, or topics in a particular clinical area, through the <a href=\"http://cks.clarity.co.uk/get-involved/\" data-hyperlink-id=\"0c074bde-5de8-4422-9129-a8f70159f002\">Getting involved</a> section of the <a href=\"https://clarity.co.uk/\" data-hyperlink-id=\"14013c32-a4f5-444f-ab3e-a8f70159f42f\">Clarity Informatics</a> website.</li><li>Stakeholders identified from the following groups are invited to review draft topics:<ul><li>Experts in the topic area.</li><li>Professional organizations and societies (for example, Royal Colleges).</li><li>Patient organizations, Clarity has established close links with groups such as Age UK and the Alzheimer’s Society specifically for their input into new topic development, review of current topic content and advice on relevant areas of expert knowledge.</li><li>Guideline development groups where the topic is an implementation of a guideline.</li><li>The British National Formulary team.</li><li>The editorial team that develop MeReC Publications.</li></ul></li><li>Reviewers are provided with clear instructions about what to review, what comments are particularly helpful, how to submit comments, and declaring interests.</li></ul><!-- end field c4fb8b6a-1691-4abc-9e9c-a7f201750b43 --><!-- begin field 64a69bf1-b8b0-479c-8711-a7f201750b43 --><h2>Patient engagement</h2><!-- end field 64a69bf1-b8b0-479c-8711-a7f201750b43 --><!-- begin field 42cc32e9-f4c4-486a-ba58-a7f201750b43 --><p>Clarity Informatics has enlisted the support and involvement of patients and lay persons at all stages in the process of creating the content which include:</p><ul><li>Topic selection</li><li>Scoping of topic</li><li>Selection of clinical scenarios</li><li>First draft internal review</li><li>Second draft internal review</li><li>External review</li><li>Final draft and pre-publication</li></ul><p>Our lay and patient involvement includes membership on the editorial steering group, contacting expert patient groups, organizations and individuals.</p><!-- end field 42cc32e9-f4c4-486a-ba58-a7f201750b43 --><!-- end item fb586e9f-4f35-47f6-a604-a7f20174d91e -->","topic":{"id":"eb346bd0-1df2-5db2-a583-a366e34cfc19","topicId":"cc107f5d-efe6-4625-840e-5c4d4656869b","topicName":"Sickle cell disease","slug":"sickle-cell-disease","lastRevised":"Last revised in November 2016","chapters":[{"id":"d2b6d668-4d29-5c50-b65d-7467cbcce2dd","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"47f9af8d-8bda-55a3-bf81-eb75a7c4f02a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4a0ece3e-fa44-5ecd-9f55-ac17384d960c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"44a5b5f9-fc8e-5024-87e3-a7e42dca3dd9","slug":"changes","fullItemName":"Changes"},{"id":"48757ec5-731a-57fd-8e39-d2cdf918179a","slug":"update","fullItemName":"Update"}]},{"id":"53ae2089-f545-5b24-99c5-a9fc620ea575","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"ffff20e4-5bc5-5c3b-bb59-858dba2fcf8d","slug":"goals","fullItemName":"Goals"},{"id":"16f85d1d-aec7-5173-9e0b-7d9456bdf3a5","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"12a41d5f-f447-5a64-868a-7648c7de9355","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5de2a0f3-a77d-5244-a401-dbd2cbcfefb3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"fc893fb4-51ec-5705-8dff-c7fba1969646","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"cc1cc5c4-df13-5e74-bde0-9f625ec4d1cf","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"02e2bd4f-75cd-5b59-9a81-c06d3bcf4d2f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2a8eb5f7-6691-505b-bd86-9620102057a3","slug":"definition","fullItemName":"Definition"},{"id":"b756c83a-dcc0-5792-b3f9-fa9416929ce3","slug":"prevalence","fullItemName":"Prevalence"},{"id":"488c0ab1-f1c0-5fbf-bd1e-e327181c2e1f","slug":"prognosis","fullItemName":"Prognosis"},{"id":"b62a5aae-0dc3-5ac0-a1b1-d3ca0a7969ac","slug":"complications","fullItemName":"Complications"}]},{"id":"9336c0e7-d5d3-5dd6-99fd-50610ced96e1","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"dd5a2bec-36ce-58c0-b0f1-4ec5d4d17c21","slug":"when-to-suspect-sickle-cell-disease","fullItemName":"When to suspect sickle cell disease"},{"id":"bdbf4e2a-7a0c-5a2e-8b9c-4a9c661409ef","slug":"diagnosis-of-sickle-cell-disease","fullItemName":"Diagnosis of sickle cell disease"},{"id":"68746f0d-607a-5db5-8949-a87a4ed29328","slug":"when-to-suspect-an-acute-sickle-cell-crisis","fullItemName":"When to suspect an acute sickle cell crisis"},{"id":"ed48dbda-a404-50cf-a290-86fafcdb9908","slug":"assessment-of-acute-crisis","fullItemName":"Assessment of acute crisis"}]},{"id":"221fb88b-b951-5835-b282-ed218b637ff0","fullItemName":"Management","slug":"management","subChapters":[{"id":"e76854fe-5d45-5d85-8591-5712daa7e4d9","slug":"screening","fullItemName":"Scenario: Screening"},{"id":"1da4d393-99a4-51c1-b354-f1742b9d8b1f","slug":"management-sickle-cell-crisis","fullItemName":"Scenario: Management - sickle cell crisis"},{"id":"2bf8553c-1641-5bdc-bbc3-2615ddc5b84c","slug":"management-chronic-complications","fullItemName":"Scenario: Management - chronic complications"},{"id":"4493185d-8907-5325-a195-a7cd7039bd68","slug":"prevention-of-complications","fullItemName":"Scenario: Prevention of complications"},{"id":"2aeac855-0e31-598c-804d-41c8d9bc643f","slug":"management-sickle-cell-trait","fullItemName":"Scenario: Management - sickle cell trait"},{"id":"5b85ac92-9286-564f-88fb-ec37a6f4102e","slug":"contraception","fullItemName":"Scenario: Contraception"}]},{"id":"a424bf70-c56c-54a4-a2e2-019ab7c27c69","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"515607d5-c2e2-5a4c-8d83-1bb5e320badf","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2148be5b-6502-5e45-b86b-e552aa3226fd","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"acc3b704-7f3d-51ed-869e-38e0309c53e5","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2a46384b-d43c-536a-9a17-4b8953d8457a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"46873f42-ab32-5894-b2fe-429a4e62161b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1dd24310-b8ac-5381-b51a-ca1f6c178d72","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7405fe0a-8432-5e64-9fe0-4d112fd89232","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"515607d5-c2e2-5a4c-8d83-1bb5e320badf","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}